New technologies for the management of pregestational diabetes mellitus

Obstetrical and Gynecological Survey

Volumn 67, Issue 3, 2012, Pages 167-175

  Lee Parritz, Aviva ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLIBENCLAMIDE; INSULIN; INSULIN GLARGINE; METFORMIN; METHYLDOPA; ORAL ANTIDIABETIC AGENT;

CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; COST EFFECTIVENESS ANALYSIS; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG CONTRAINDICATION; DRUG SAFETY; FETUS MALFORMATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KIDNEY AGENESIS; KIDNEY FAILURE; LUNG HYPOPLASIA; MATERNAL HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOHYDRAMNIOS; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; REVIEW; STOMACH PARESIS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PREGNANCY; PREGNANCY IN DIABETICS; TECHNOLOGY;

EID: 84859081580     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31824bb538     Document Type: Review

References (51)

1. McIntyre HD, Thomae MK, Wong SF, et al. Pregnancy in type 2diabetes mellitus - problems & promises. Curr Diabetes Rev. 2009;3:190-200.
2. Albrecht SS, Kuklina EV, Bansil P, et al. Diabetes trends among delivery hospitalizations in the U.S., 1994-2004. Diabetes Care. 2010;33:768-773.
3. Balsells M, Garcia-Patterson A, Gich I, et al. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94:4284-4291.
4. Feltbower RG, Bodansky HJ, Patterson CC, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results of the Yorkshire Registry of diabetes in children and young adults. Diabetes Care. 2008;31:922.
5. Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality isnot drug-associated but linked to comorbidities. Am J Med. 2011;124:1028-1035.
6. Jacobson AM, Musen G, Ryan CM, et al. Long-term effect ofdiabetes and its treatment on cognitive function. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. N Engl J Med. 2007;356.
7. Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression ofdiabetic retinopathy during pregnancyin women with type 2 diabetes. Diabetologia. 2010;53:1076-1083.
8. Purdy LP, Hantsch CE, Molitch ME, et al. Effect ofpregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care. 1996;19:1067-1074. (Pubitemid 26334253)
9. Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabstes Care. 1995;18:572.
10. Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies (Technical Review). Diabetes Care. 2004;27: 1458-1486. (Pubitemid 38680000)
11. Parker JA, Conway DL. Diabetic ketoacidosis inpregnancy. Obstet Gynecol Clin North Am. 2007;34:533-543.
12. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy. Diabetes Care. 2008;31:1060-1079.
13. Yang X, Borg LA, Eriksson UJ. Altered metabolism and superoxide generation in neural tissue of rat embryos exposed to high glucose. Am J Physiol. 1997;272:E173-E180.
14. Kitzmiller JL, Buchanan TA, Kjos S, et al. Pre-conception care ofdiabetes, congenital malformations, and spontaneous abortions. Diabetes Care. 1996;19:514-541. (Pubitemid 26143759)
15. Tieu J, Middleton P, Crowther CA. Preconception care for diabetic women for improving maternal and infant health. Cochrane Database Syst Rev. 2010:CD007776.
16. Confidential Enquiry Into Maternal and Child Health. Pregnancy in Women With Type 1 and Type 2 Diabetes in 2002-03, England, Wales and Northern Ireland. London, United Kingdom: CEMACH; 2005.
17. Wahabi HA, Alzeidan RA, Bawazeer GA, et al. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2010;10:63.
18. Inkster ME, Fahey TP, Donnan PT, et al. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy and Childbirth. 2006;6:30.
19. Phelps RL, Metzger BE, Freinkel N. Carbohydrate metabolism inpregnancy: XVII, diurnal profiles of plasma glucose, insulin, free fatty acids, triglycerides, cholesterol, and individual amino acids in late normal pregnancy. Am J Obstet Gynecol. 1981;140:730-736. (Pubitemid 11046636)
20. Parretti E, Mecacci F, Papini M, et al. Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care. 2001;24:1319-1323. (Pubitemid 33716414)
21. Yogev Y, Ben-Haroush A, Chen R, et al. Undiagnosed asymptomatic hypoglycemia: diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet Gynecol. 2004;104:88-93. (Pubitemid 40458909)
22. Riskin-Mashiah S, Damti A, Younes G, et al. Normal fasting plasma glucose levels during pregnancy: a hospital-based study. J Perinat Med. 2011;39:209-211.
23. Langer O, Levy J, Brustman L, et al. Glycemic control ingestational diabetes mellitus - how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol. 1989;161:646-653. (Pubitemid 19252777)
24. Hiilesmaa V, Suhonen L, Teramo K. Glycaemic control isassociated with pre-eclampsia but not with pregnancyinduced hypertension in women with type 1 diabetes mellitus. Diabetologia. 2000;43:1534-1539. (Pubitemid 32734860)
25. Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome intype 1 diabetic women with microalbuminuria. Diabetes Care. 2001;24:1739-1744. (Pubitemid 33716475)
26. Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome intype 1 diabetic women with microalbuminuria or diabetic nephropathy. Effects of intensified antihypertensive therapy. Diabetes Care. 2009;32:38-44.
27. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-2451. (Pubitemid 43855047)
28. Buchanan ML, Easterling TL, Carr DB, et al. Clonidine pharmacokinetics inpregnancy. Drug Metab Dispos. 2009;37: 702-705.
29. Perriello G, Pampanelli S, Porcellati F, et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and crossover trial. Diabet Med. 2005;22:606-611. (Pubitemid 40593137)
30. Anderson JH Jr, Brunelle RL, Keohane P, et al; for the Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1249-1255. (Pubitemid 27251653)
31. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008;198:186.
32. Mathiesen E, Kinsley B, Amiel SA, et al; on behalf of the Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetes pregnancy: a randomized trial of insulin aspart vs. human insulin in 322 pregnant women. Diabetes Care. 2007;30:771-776. (Pubitemid 46556565)
33. Fulcher GR, Gilbert RE, Yue DK. Glargine issuperior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting glucose levels during intensive insulin therapy. Intern Med J. 2005;35:536-542. (Pubitemid 41291382)
34. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogs versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184-189.
35. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations ofreceptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49: 999-1005. (Pubitemid 30349423)
36. Pollex EK, Feig DS, Lubetsky A, et al. Insulin glargine safety inpregnancy: a transplacental transfer study. Diabetes Care. 2010;33:29-33.
37. Pantalone KM, Faiman C, Olansky L. Insulin glargine: use inpregnancy. Endocr Pract. 2011;25:1-25.
38. Loukovaara S, Immonen I, Teramo KA, et al. Progression ofretinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care. 2003;26:1193-1198. (Pubitemid 36929271)
39. Gilbert C, Valois M, Koren G. Pregnancy outcome after first trimester exposure to metformin: a meta analysis. Fertil Steril. 2006;86:658-663.
40. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod. 2004;19:1323-1330. (Pubitemid 38807703)
41. Rowan JA, Hague WM, Gao W, et al; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003-2015. (Pubitemid 351656455)
42. Elliott BD, Langer O, Schenker S, et al. Insignificant transfer ofglyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165:807-812.
43. Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects ofglyburide on insulin secretion and glucose uptake in humans. Diabetes Care. 1991;14:724-727.
44. Langer O, Conway DL, Berkus MD, et al. A comparison ofglyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343:1134.
45. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol. 2011;25:51-63.
46. Fatourechi MM, Kudva YC, Murad MH, et al. Hypoglycemia with intensive insulin therapy: a systematic review and metaanalyses of randomized trials of continuous subcutaneous insulin infusion vs. multiple daily injections. J Clin Endocrinol Metab. 2009;94:729-740.
47. Chen R, Ben-Haroush A, Weissmann-Brenner A, et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol. 2007;197:404.e1-404.e5.
48. Bruttomesso D, Bonomo M, Costa S, et al; the IGCSIIP (Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy). Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab. 2011;37:426-431.
49. Mukhopadhyay A, Farrell T, Fraser RB, et al. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and meta-analysis or randomized, controlled trials. Am J Obstet Gynecol. 2007;197:447-456. (Pubitemid 350007372)
50. Pickup JC, Freeman SC. Glycaemic control intype 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343.
51. Murphy HR, Rayman G, Lewis K, et al. Effectiveness ofcontinuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ. 2008;337.